Division of Health Science, Department of Medical Science, University of Guanajuato - Campus León, Leon de los Aldama, Mexico.
Health Research Division, High Specialty Medical Unit, Hospital of Gynecology and Pediatrics # 48, Mexican Institute of Social Security, León, Guanajuato, Mexico.
Metab Syndr Relat Disord. 2022 Jun;20(5):295-302. doi: 10.1089/met.2021.0141. Epub 2022 Mar 23.
Fatty acid-binding protein 4 (FABP4) is an adipokine that plays a causative role in obesity and diabetes. In a stratified cross-sectional study with adolescents, we explored whether changes in FABP4 are already present in lean adolescents, provided they display elements of insulin resistance (IR). Adolescents were divided in four groups according to body mass index and homeostasis model assessment-IR. In metabolically unhealthy lean (MUL) adolescents (MUL, lean with IR), FABP4 was 33% higher than in healthy counterparts (metabolically healthy lean [MHL]). Obese adolescents without IR (metabolically healthy obesity [MHO]) had 50% higher levels of FABP4 than their lean counterparts (MHL), while levels of FABP4 in obese adolescents with IR (metabolically unhealthy obese [MUO]) were 220% higher than those of MUL adolescents. The differences were significant at least with < 0.005. MUO > MHO > MUL. Our data demonstrate that the known FABP4 defect in adults with obesity also occurs in youth and even in lean adolescents, suggesting an early association between impaired glucose metabolism and FABP4 irrespective of body weight. FABP4 was more sensitive in discerning each of our 4 subgroups than either adiponectin or leptin. Moreover, evidence for a putative early adiponectin resistance in MUL suggests a combined defect in these adolescents that call for early detection and prevention of the metabolic disturbance that should stay away from concentrating only in subjects with obesity. Our data may serve to draw the considerable attention that is currently paid to FABP4 to the adolescent population, irrespective of the presence of obesity. Further studies with larger cohorts and analyses of visceral and liver fat are warranted.
脂肪酸结合蛋白 4(FABP4)是一种脂肪因子,在肥胖和糖尿病中起因果作用。在一项针对青少年的分层横断面研究中,我们探讨了即使在表现出胰岛素抵抗(IR)迹象的瘦青少年中,FABP4 是否已经发生变化。 根据体重指数和稳态模型评估-IR,将青少年分为四组。 在代谢不健康的瘦(MUL)青少年(MUL,瘦伴 IR)中,FABP4 比健康对照组(代谢健康的瘦 [MHL])高 33%。 无 IR 的肥胖青少年(代谢健康肥胖 [MHO])的 FABP4 水平比其瘦对应物(MHL)高 50%,而有 IR 的肥胖青少年(代谢不健康肥胖 [MUO])的 FABP4 水平比 MUL 青少年高 220%。 这些差异至少具有统计学意义(<0.005)。 MUO > MHO > MUL。 我们的数据表明,肥胖成年人中已知的 FABP4 缺陷也发生在青少年中,甚至在瘦青少年中,这表明葡萄糖代谢受损与 FABP4 之间存在早期关联,而与体重无关。 FABP4 在辨别我们的 4 个亚组中的每一个方面都比脂联素或瘦素更敏感。 此外,在 MUL 中存在潜在的早期脂联素抵抗的证据表明,这些青少年存在联合缺陷,需要早期发现和预防代谢紊乱,而代谢紊乱不应仅集中在肥胖人群中。 我们的数据可以引起目前对 FABP4 的关注,无论青少年是否存在肥胖。 还需要进行更大队列的研究和内脏脂肪和肝脂肪的分析。